ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Eiko LifeSciences held its 49th Annual General Meeting on September 22, 2026. The meeting transacted business, including adoption of financial statements and appointment of directors.
Eiko Lifesciences informed exchanges that it sent the AGM notice and Annual Report weblink to shareholders who have not registered email addresses.
Eiko Lifesciences Limited has issued a notice for its 49th Annual General Meeting scheduled for September 22, 2026, to discuss financial statements and related matters.
Eiko Lifesciences Limited has announced its 49th Annual General Meeting, scheduled for September 22, 2026. The company has also filed its Annual Report for FY 2025-26.
Eiko Lifesciences Limited will hold its 49th Annual General Meeting on September 22, 2026, via video conferencing to transact ordinary and special business.
Eiko Lifesciences Limited has appointed Mr. Suraj Mahadev Gaikwad as an Additional Independent and Non-Executive Director, subject to approval by shareholders at the upcoming Annual General Meeting.
Eiko Lifesciences' board meeting accepted Ms. Hasti Doshi's resignation and approved Mr. Suraj Mahadev Gaikwad's appointment as Additional Director. The AGM is scheduled for September 22, 2026.
Eiko Lifesciences disputes an alleged 1986 corporate guarantee claim of ₹0.58 Crore from IDBI Bank. The company is pursuing legal remedies and denies liability.
Eiko LifeSciences Limited has allotted 3,05,000 equity shares following the conversion of warrants. The company received Rs. 1.26 Crore, representing the balance 75% payment for these shares.
Eiko Lifesciences Ltd reported revenue from operations of ₹16.7 Cr (+56.1% YoY) and net profit of ₹1.5 Cr (+36.4% YoY) for Q1 FY27.
Eiko Lifesciences will hold a board meeting on 12th August, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ending 30th June, 2026.
This is a routine quarterly shareholding pattern filing for Eiko Lifesciences Ltd for the quarter ended June 30, 2026.
Eiko Lifesciences Ltd reported revenue from operations of ₹18.3 Cr (+61.9% YoY) and net profit of ₹1.5 Cr (+25.0% YoY) for Q4 FY26.
Eiko Lifesciences reported standalone annual revenue of ₹44.26 Crore for FY2026. The board also appointed M/s NP Rajput & Co as internal auditors for FY2026-27.
Eiko Lifesciences filed its Annual Secretarial Compliance Report for the year ended March 2026. The auditor confirmed general regulatory compliance with no material adverse observations.
Eiko Lifesciences Limited scheduled a board meeting for May 26, 2026, to approve audited financial results. The trading window remains closed until 48 hours post-declaration.
Eiko Lifesciences Ltd. informed the exchange that it is not classified as a 'Large Corporate' as of March 31, 2026. Consequently, the SEBI framework for fund raising via debt securities is not applicable, and no initial or annual disclosures are required for the financial year.
Eiko Lifesciences Limited submitted a certificate under Regulation 74(5) of SEBI Regulations for the quarter ended March 31, 2026. The company’s Registrar, Bigshare Services Pvt. Ltd., confirmed that no dematerialization requests for equity shares were received during this period.